In addition, we find that extracellular ASOs are an effective approach to reduce APP protein levels in human neurons, indicating that this therapeutic approach has considerable potential in monogenic AD due to SORL1, APP, or PSEN1 mutations. Here, PSEN1 is linked to Alzheimer disease.